Efficacy of antiviral therapy during the second or the third trimester for preventing mother-to-child hepatitis B virus transmission: a systematic review and meta-analysis

Yang, Xiuhan; Zhong, Xu; Liao, Huihua; Lai, Yongchang

doi:10.1590/s1678-9946202062013

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postponement of treatment to a point later than 32 weeks of gestation may result in an insufficient duration of treatment and suboptimal viral load reduction at delivery. 10,20 Guidelines from the American Association for the Study of Liver Diseases and the Asian Pacific Association for the Study of the Liver recommend initiation of treatment at 28 to 32 weeks of gestation. 9,21 The present study demonstrated a feasible framework for triage of nearly all pregnant women with high viral loads before their dates of delivery.…”

Section: Discussionmentioning

confidence: 99%

Acceptance of antiviral treatment and enhanced service model for pregnant patients carrying hepatitis B

Hui

Cheung

et al. 2020

Hong Kong Med J

View full text Add to dashboard Cite

A service model was established for pregnant women with positive screening results for hepatitis B surface antigen (HBsAg) at Queen Mary Hospital in Hong Kong. All women were offered a blood test for hepatitis B virus (HBV) DNA level during the first antenatal visit. Women with HBV DNA levels of ≥200 000 IU/mL received counselling from hepatologists regarding treatment with antenatal tenofovir disoproxil fumarate (TDF) 300 mg daily. Methods: This retrospective review included women attending our antenatal clinic who exhibited positive HBsAg screening results from 15 May 2017 to 31 December 2019. The proportions of women with positive HBsAg, DNA test acceptance, hepatological review, and TDF acceptance during pregnancy were reviewed. Results: In total, 375 (2.9%) of 13 082 pregnant women had positive HBsAg screening results. Blood tests for HBV DNA and hepatological reviews were offered to 273 women who had not undergone hepatological review prior to pregnancy; the acceptance rate was 97.8%. Sixty (22.6%) pregnant

show abstract

Section: Discussionmentioning

confidence: 99%

Acceptance of antiviral treatment and enhanced service model for pregnant patients carrying hepatitis B

Hui

Cheung

et al. 2020

Hong Kong Med J

View full text Add to dashboard Cite

show abstract

“…Numerous studies have emerged in recent years that favor the use of tenofovir disoproxil fumarate (TDF) because of its high efficacy and safety profile in addition to its high barrier to resistance (Table 4). [6][7][8][9][10][11][12] Patients who become pregnant while already maintained on HBV treatment should be assessed for both the appropriateness of the drug therapy and their response to treatment. Patients should be continued on HBV antiviral therapy (AVT) throughout the pregnancy and after delivery in the long term.…”

Section: Hepatitis B Virusmentioning

confidence: 99%

Viral Hepatitis in Pregnancy: An Update on Screening, Diagnosis, and Management

Sanghi

Lindenmeyer

2021

Clinical Liver Disease

View full text Add to dashboard Cite

Viral hepatitis in pregnancy is common; accordingly, there is a need for evolved best practices in the approach to treatment of this special population. 1 Historically, the major limitation to standardization of evaluation and management of pregnant patients with viral hepatitis had been the availability of high-quality evidence and consensus expert opinion. In this article, we review the updated evidence for the screening, diagnosis, and management of acute and chronic viral hepatitis in pregnancy.Viral hepatitis in pregnancy increases the risk for pregnancy-related complications, as well as the risks associated with acute and chronic liver disease for both the mother and the infant as a result of mother-to-child transmission (MTCT) (Table 1). 1 A comprehensive and multidisciplinary approach to the management of viral hepatitis in pregnancy is necessary to reduce morbidity, mortality, and need for liver transplantation. This methodology involves early identification by screening, use of prevention techniques, encouragement of safe breastfeeding, treatment of infection, and immunoprophylaxis (Tables 1 and 2). HePaTiTis a virUsHepatitis A virus (HAV) typically has minimal impact on pregnancy. Testing in acute illness includes serum anti-HAV

show abstract

Efficacy of antiviral therapy during the second or the third trimester for preventing mother-to-child hepatitis B virus transmission: a systematic review and meta-analysis

Abstract: This is an open-access article distributed under the terms of the Creative Commons Attribution License.

Cited by 2 publications

References 26 publications

Acceptance of antiviral treatment and enhanced service model for pregnant patients carrying hepatitis B

Acceptance of antiviral treatment and enhanced service model for pregnant patients carrying hepatitis B

Viral Hepatitis in Pregnancy: An Update on Screening, Diagnosis, and Management

Contact Info

Product

Resources

About